Nova Eye Medical (EYE) Discussion, page-2886

There are a few routes to a billion dollar plus market cap. Progress with 2RT would probably be the quickest. A deal would probably triple the price in a fairly short amount of time as the market will finally begin to value that opportunity, and it would be quickly followed by further announcements related to the European commercialisation and the pivotal clinical trial (which is all ready to go). For iTrack Advance it will probably be slower and more gradual. As they release stronger financial results the price will increase accordingly. The sufficient revenue/earnings to warrant a billion dollar plus market cap should quite easily be achieved eventually assuming that we see an indication expansion (e.g. closed angle glaucoma, where iTrack Advance will be the ONLY MIGS treatment option), global adoption (China seems particularly lucrative), as well as if the interventional glaucoma movement continues to gain momentum in the medical community (as that would mean it becomes the standard of care to treat glaucoma with MIGS first, rather than drops). Other things like new products (expect a next gen molteno device to be announced soon) and anything else they have in the R&D pipeline should help as well.

Share price itself will also be a bit of a catalyst. When this moves above a dollar it should begin to become more accessible to institutional investors. It's not just fundamentals, they are already great, however it is so difficult for large investors to get a meaningfully large position at these prices that they are having to wait on the sidelines (which probably explains why the price has been slow to value the rapidly improving fundamentals). Hopefully over the next few weeks that issue will be solved by a rapid increase in the share price. 50c should unlock a sufficient amount of liquidity for these larger investors to begin to accumulate on market